Guarneri V, Piacentini F, Ficarra G, et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009 vol.20-pp.1193–8.
Grotting J.C., Urist M.M., Maddos W.A., Vasconez L.O. (1989) Conventional TRAM flap versus free microsurgical TRAM flap for immediate breast reconstruction. Plast Reconstr Surg., 83: 828–841.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012 Jan; vol. 13(1).pp 25–32.
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH Trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010 Jan vol. 30;375.-pp 377–84.
Gilles H.D, Millard D.R. (1957) Principles and Art of Plastic Surgery. Boston: Little Brown & Company.
Holmström H. (1979) The free abdominoplasty flap and its use in breast reconstruction. Scand J Plast Reconstr Surg., 13: 423–427.
Hartrampf C.R. Jr. (1987) Breast reconstruction with a transverse abdominal island flap. A retrospective evaluation of 335 patients. Perspect Plast Surg., 1: 123.
Hartrampf C.R., Scheflan M., Black P.W. (1982) Breast reconstruction with a transverse abdominal island flap. Plast Reconstr Surgery, 69: 216–225.
Hokin J.A., Silfverskiold K.L. (1987) Breast reconstruction without an implant: Results and complications using an extended latissimus dorsi flap. Plast Reconstr Surg., 79: 58–66.
Höhler H. (1977) Carcinoma of the breast. Reconstructive surgery. Langenbecks Arch Chir., 345: 78–86.
Hayward J. (1983) In: Harris J.R., Hellman S., Silen W., editor. Conservative Management of Breast Cancer. Philadelphia: Lippincott. The Guy’s Hospital trials on breast conservation.
Holmes YMN FA, Espina VA, Liotta LA, et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 2011; vol.29(Suppl.):29. [abstr 506].
Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012 Dec;48 vol. 18.-pp 3342–54.Heys SDHA, Sarkar TK, Ogston KN, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial Aberdeen Breast Group. Suppl. X. Clin Breast Cancer 2002 Oct;3(S2) pp:69–74.
http://clinicaltrials.gov/show/NCT01772472.
Jones RL, Salter J, A’Hern R, et al. Relationship between oestrogen receptor status and proliferation in predicting response and longterm outcome to neoadjuvant chemotherapy for breast cancer. BreastCancer Res Treat 2010. – vol.119- pp.315–23.
Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 2006 vol.7-pp 869–74.
-
Jones RL, Salter J, A’Hern R, et al. The prognostic significance ok Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009 vol.116-pp.53–68
Kroll S.S., Khoo A., Singletary S.E. et al. (1999) Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up. Plast Reconstr Surg.,104: 421–425.
Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007 vol. 18-pp.1927–34.
Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999 Feb;17 vol. 2.-pp 460–9.
Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 2011 Sep;47 vol. 14.-pp:2084–90.
Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 2008 vol. 61-pp.569–77.
Little J.W. (1984) Nipple areola reconstruction. Clin Plast Surg., 11: 351–364.
Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemictreatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005 Feb 2;97 vol. 3.-pp 188–94.
McGuire KP, Toro-Burguete J, Dang H, et al. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 2011 Oct;18 vol. 11.-pp 3149–54.
Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999 Jan;vol. 10(1).-pp 47–52.
Miglietta L, Vanella P, Canobbio L, et al. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology 2010.-vol.79- pp.255–61.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981 vol.47-pp.207–21.
McCraw J.B., Horton C.E., Grossman J.A. et al. (1987) An early appraisal of the methods of tissue expansion and the transverse rectus abdominis musculocutaneous flap in the reconstruction of the breast following mastectomy. Ann Plast Surg.,18: 93–113.
Muhlbauer W., Olbrisch R. (1977) The latissimus dorsi myocutaneous flap for breast reconstruction. Chir Plast (Berlin), 4: 27.
Noguchi M, Saito Y, Nishijima H, et al. The psychological and cosmetic aspects of breast conserving therapy compared with radical mastectomy. Surg Today 1993;23 vol. 7.-pp 598–602.
Nissen MJ, Swenson KK, Ritz LJ, Farrell JB, Sladek ML, Lally RM. Quality of life after breast carcinoma surgery: a comparison of three surgical procedures. Cancer 2001 Apr 1;91 vol. 7.-pp 1238–46.
Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 2007 Mar; 50vol. 4.-pp 409–17.
Ohzawa H, Sakatani T, Niki T, Yasuda Y, Hozumi Y. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab. Breast Cancer 2012 Oct 30. http://dx.doi.org/10.1007/s12282-012-0424-4. [epub ahead of print].
Petit J.Y., Lohsiriwat V., Clough K.B., Sarfati I. et al. (2011) The oncologic outcome and immediate surgical complications of lipofilling in breast cancer patients: a multicenter study — Milan-Paris-Lyon experience of 646 lipofilling procedures. Plast Reconstr Surg., 128(2): 341–6.
Petit T, Wilt M, Velten M, et al. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Breast Cancer Res Treat 2010 vol.124-pp.387–91.
Parkin D.M. (2009) Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer., 45: 1649–1653.
Peintinger F, Kuerer HM, Anderson K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 2006 Nov;13(11):1443–9.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008 Feb 10;26 vol. 5.-pp:778–85.
Radovan C. (1982) Breast reconstruction after mastectomy using the temporary expander. Plast Reconstr Surg., 69: 195–208.
Robbins T.H. (1979) Rectus abdominis myocutaneous flap for breast reconstruction. Aust N Z J Surg., 49: 527–530.
Ring A, Webb A, Ashley S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol 2003 Dec 15;21 vol. 24.- pp 4540–5.
Semiglazov, V. F., Dashyan, G. A., Semiglazov, V. V., Petrenko, O.L., Komyahov, A., Paltuev, R. M., & Matzko, D. (2015). P198 Prognostic value of breast cancer subtypes: from phase 2 randomized trial of neoadjuvant therapy. The Breast, 2015 vol.(suppl.1)24, S92.
Shchepotin I., Sydorchuk O., Motuzyuk I. (2010) Conception of choice the operation to breast cancer patients — Results of treatment 1199 patients. Eur J Canс Suppl., 8(3): 137.
Spear S.L., Convit R., Little J.W. (1989) 3rd Intradermal tattoo as an adjunct to nipple-areola reconstruction. Plast Reconstr Surg., 83: 907–911.
Scheflan M., Dinner M.I. (1983) The transverse lower rectus abdominis operation for breast reconstruction. Plast Reconstr Surg., 72: 819.
Schneider W.J., Hill H.L., Brown R.G. (1977) Latissimus dorsi myocutaneous flap for breast reconstruction. Br J Plast Surg., 30: 277–281.
Steyerberg EW. In: Clinical prediction model. A practical approach to development, validation and updating. New York: Springer Edition; 2009, pp. 94–6.
Slamon D, EiermannW, RobertN, et al. Adjuvant trastuzumab inHER2- positive breast cancer. N Engl J Med 2011 Oct vol. 6;365(14).- pp1273–83.
Schneeweiss ACS, Hickish T, Harvey V, et al. Neoadjuvant pertuzumab and trastuzumab concurrent of sequential with an anthracycline containing or concurrent with an anthracycline free regime: a randomized phase II study (TRYPHAENA). Cancer Res 2011;71(24 Suppl.): 112s–3s.
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007 Oct 1;25 vol. 28.-pp 4414–22.
Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002 Mar 15;20vol. 6-pp1456–66.
Tanei T, Shimomura A, Shimazu K, et al. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011 vol. 37-pp. 155–61.
Thomas E, Holmes FA, Smith TL, et al. The use of alternate, noncross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004 vol.22-pp.2294–302.
Tanzini I. (1906) Spora il mio nuova processo di amputazione della mammella. Riforma Medica., 22: 757.
Teimourian B., Adham M.N. (1983) Louis Ombredanne and the origin of muscle flap use for immediate breast mound reconstruction. Plast Reconstr Surg., 72: 907–910.
Toth B.A., Glafkides M.C. (1990) Immediate breast reconstruction with deepithelialized TRAM-flaps: Techniques for improving breast reconstruction Plast. Reconstr. Surg.
Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012 Feb;13 vol. 2.-pp135–44.
Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol 2010 Apr 20;28(12):2024–31. Untch M, Fasching PA, Konecny GE, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO Trial of the AGO and GBG Study Groups. J Clin Oncol 2011 Sep 1;29 vol. 25.-pp 3351–7.
von Minckwitz GBJ, Costa S, Denkert C, et al. Neoadjuvant chemotherapy adapted by Interim response improves overall survival of primary breast cancer patients e results of the GeparTrio trial. [Abstract]. Cancer Res 2011 December 15;71 vol. 24.-pp:103s.
van der Hage JH, vdVC, Mieog SJSD. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev Pub2 2007; vol. 2. Art. No.: CD005002.
von Minckwitz GKM, Kuemmel S, Fasching PA, et al. GBG and AGOB Study Groups. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: results from the German neoadjuvant meta-analysis. J Clin Oncol 2011;vol. 29(Suppl.). [abstr 1028].
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012 May 20;30 vol. 15.-pp 1796–804.
van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 2011 vol.37-pp.422–30.
Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 2011 Dec;20 vol. 6.-pp 485–90.
Valachis A, Nearchou A, Lind P, Mauri D. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Breast Cancer Res Treat 2012 Oct; vol. 135(3).-pp 655–62.
Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012 Nov 8;367 vol. 19.- pp 1783–91.
Ververs JM, Roumen RM, Vingerhoets AJ, et al. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 2001 May; vol. 37(8).- pp 991–9.
Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001. Vol.30. pp:96–102.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010 vol.11-pp.174–83.
|
